Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Brainstorm’s Alzheimer’s Key Opinion Leader Event

Brainstorm’s July 8, 2020 Key Opinion Leader (KOL) Webinar on the Company's Alzheimer's Disease (AD) Clinical Program.

Corresponding Presentation

Recent News
Apr 19, 2021

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...

Mar 24, 2021

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial...

Feb 23, 2021

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will...

View All

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds